Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
PBP binds ATP, opioids and phosphatidylethanolamine, exhibiting a lower affinity for phosphatidylinositol and phosphatidylcholine. This serine protease inhibitor inhibits thrombin, neuropsin and chymotrypsin but not trypsin, tissue type plasminogen activator and elastase. PBP contains hippocampal cholinergic neurostimulating peptide (HCNP), which may be involved in the function of the presynaptic cholinergic neurons of the central nervous system. HCNP increases the production of choline acetyltransferase but not acetylcholinesterase.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 23 kDa morphine-binding protein; epididymis luminal protein 210; epididymis secretory protein Li 34; epididymis secretory protein Li 96; HCNP; HCNPpp; Hippocampal cholinergic neurostimulating peptide; KIAA0299; MOCA; Neuropolypeptide h3; P23K; PEBP-1; Phosphatidylethanolamine-binding protein 1; PPBP; prostatic binding protein; Prostatic-binding protein; Raf kinase inhibitor protein; Raf kinase inhibitory protein; Raf-1 inhibitor protein; Raf-1 kinase inhibitor protein; RKIP
Gene Aliases: HCNP; HCNPpp; HEL-210; HEL-S-34; HEL-S-96; PBP; Pbp1; Pbpr; PEBP; PEBP-1; PEBP1; RKIP; zgc:56033; zgc:76942